Catalyst Pharmaceuticals Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
CPRX

Price
6.92
Stock movement up
+0.10 (1.47%)
Company name
Catalyst Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
711.24M
Ent value
559.62M
Price/Sales
18.57
Price/Book
3.23
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
22.35
Forward P/E
8.44
PEG
-
EPS growth
26.50%
1 year return
23.35%
3 year return
21.69%
5 year return
25.42%
10 year return
22.76%
Last updated: 2022-05-19

DIVIDENDS

CPRX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E22.35
Price to OCF10.94
Price to FCF10.95
Price to EBITDA16.60
EV to EBITDA13.06

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales18.57
Price to Book3.23
EV to Sales14.61

FINANCIALS

Per share

Loading...
Per share data
Current share count102.78M
EPS (TTM)0.29
FCF per share (TTM)0.60

Income statement

Loading...
Income statement data
Revenue (TTM)38.31M
Gross profit (TTM)21.11M
Operating income (TTM)42.58M
Net income (TTM)31.82M
EPS (TTM)0.29
EPS (1y forward)0.82

Margins

Loading...
Margins data
Gross margin (TTM)55.09%
Operating margin (TTM)111.16%
Profit margin (TTM)83.06%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash178.37M
Net receivables10.55M
Total current assets221.19M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets246.97M
Accounts payable5.14M
Short/Current long term debt3.81M
Total current liabilities22.94M
Total liabilities26.75M
Shareholder's equity220.22M
Net tangible assets220.22M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)65.04M
Capital expenditures (TTM)110.00K
Free cash flow (TTM)64.93M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity14.45%
Return on Assets12.88%
Return on Invested Capital14.45%
Cash Return on Invested Capital29.48%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.75
Daily high7.01
Daily low6.74
Daily Volume1.05M
All-time high8.57
1y analyst estimate11.00
Beta1.29
EPS (TTM)0.29
Dividend per share-
Ex-div date-
Next earnings date8 Aug 2022

Downside potential

Loading...
Downside potential data
CPRXS&P500
Current price drop from All-time high-19.25%-18.47%
Highest price drop-94.25%-56.47%
Date of highest drop12 Nov 20129 Mar 2009
Avg drop from high-61.00%-11.34%
Avg time to new high299 days12 days
Max time to new high3146 days1805 days
COMPANY DETAILS
CPRX (Catalyst Pharmaceuticals Inc) company logo
Marketcap
711.24M
Marketcap category
Small-cap
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Employees
76
SEC filings
CEO
Patrick McEnany
Country
USA
City
Coral Gables
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and c...
May 17, 2022
Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders might be concerned after seeing the share price drop 14% in...
May 11, 2022
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
May 10, 2022
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and No Fun...
May 10, 2022
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
May 9, 2022
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ETCORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a com...
April 25, 2022
Arcos Dorados (ARCO): A fast food franchisee serving Latin America. Catalyst Pharmaceuticals (CPRX): This biopharmaceutical firm focuses on rare debilitating neuromuscular and neurodegenerative diseas...
April 5, 2022
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 13...
March 29, 2022
Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
March 16, 2022
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-T...
March 16, 2022
Next page